Gynica is changing the culture of gynecological treatment through clinically-proven, cannabinoid-based solutions.

Gynica is a medical company at the forefront of therapeutic cannabis research in the field of women’s health. Our team develops medical treatments based on innovative technology and an advanced understanding of the pharmacological effects of cannabinoids that target specifically female symptoms and diseases. Led by Professor Moshe Hod(1), an internationally renowned expert in the field of women’s health, Gynica brings women scientifically-proven and thoroughly-tested solutions to pressing health issues unique to women.

We believe that cannabinoids are the missing piece in the treatment of gynecological disorders.

Scientific research has shown that the cannabis plant is unique for women(2)after the brain, the female reproductive system is the organ with the most endocannabinoid receptors in the human body.(3)

Taking advantage of the fast-growing cannabis movement world-wide, Gynica’s collaboration with Lumir Lab(4) has arrived as the innovative leader in changing the culture of gynecological treatment.

  • President of the European Association of Perinatal Medicine (EAPM) and Professor of Gynecology at the Tel Aviv University Faculty of Medicine
  • Numerous studies have been published on cannabinoid signaling in female reproductive events, including preimplantation embryo development, oviductal embryo transport, embryo implantation, placentation, and parturition.
    ACS Chem Neurosci
  • How important are sex differences in cannabinoid action?
    British Journal of Pharmacology
  • Lumir Lab is the first and only lab licensed by the Ministry of Health to research cannabis as it relates to women’s health.